



21st June 2011

Dasatinib 20, 50 & 70 mg tablets

The New Therapies Subgroup discussed the above drug at a meeting on the 17th July 2007 and June 2011. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the therapeutic use of dasatinib (Sprycel[®]) for the management of chronic, accelerated or blast phase chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy including imatinib, and Philadelphia chromosome positive acute lymphoblastic leukaemia and lymphoid blast CML with resistance or intolerance to prior therapy.

The group recommends that dasatinib is used in line with guidance available from the Greater Manchester and Cheshire Cancer Network and in line with the GM cancer commissioning process.

This recommendation relates only to the treatment algorithms submitted to the NTS in July 2007. Please contact the Greater Manchester and Cheshire Cancer Network for details of the treatment algorithms (www.gmccn.nhs.uk).

Review Date: June 2013

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.